Devices in the management of advanced, chronic heart failure
- 11 December 2012
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 10 (2) , 98-110
Abstract
Medical devices are often life-saving therapies in patients with advanced heart failure whose condition worsens despite optimal medical therapy. Drs Abraham and Smith expertly review the development of cardiac resynchronization therapy and left ventricular assist devices, describe the current challenges associated with these treatment strategies, and speculate on future advances in this fast-moving field. Heart failure (HF) is a global phenomenon, and the overall incidence and prevalence of the condition are steadily increasing. Medical therapies have proven efficacious, but only a small number of pharmacological options are in development. When patients cease to respond adequately to optimal medical therapy, cardiac resynchronization therapy has been shown to improve symptoms, reduce hospitalizations, promote reverse remodelling, and decrease mortality. However, challenges remain in identifying the ideal recipients for this therapy. The field of mechanical circulatory support has seen immense growth since the early 2000s, and left ventricular assist devices (LVADs) have transitioned over the past decade from large, pulsatile devices to smaller, more-compact, continuous-flow devices. Infections and haematological issues are still important areas that need to be addressed. Whereas LVADs were once approved only for 'bridge to transplantation', these devices are now used as destination therapy for critically ill patients with HF, allowing these individuals to return to the community. A host of novel strategies, including cardiac contractility modulation, implantable haemodynamic-monitoring devices, and phrenic and vagus nerve stimulation, are under investigation and might have an impact on the future care of patients with chronic HF.Keywords
This publication has 177 references indexed in Scilit:
- Survival Benefit of Implantable Cardioverter-Defibrillators in Left Ventricular Assist Device–Supported Heart Failure PatientsJournal of Cardiac Failure, 2012
- National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries, 1998-2008JAMA, 2011
- Transvenous phrenic nerve stimulation for the treatment of central sleep apnoea in heart failureEuropean Heart Journal, 2011
- Site of latest activation in patients eligible for cardiac resynchronization therapy: Patterns of dyssynchrony among different QRS configurations and impact of heart failure etiologyAmerican Heart Journal, 2011
- Acquired Von Willebrand syndrome is an early-onset problem in ventricular assist device patientsEuropean Journal of Cardio-Thoracic Surgery, 2011
- Clinical, Molecular, and Genomic Changes in Response to a Left Ventricular Assist DeviceJACC, 2011
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Second INTERMACS annual report: More than 1,000 primary left ventricular assist device implantsThe Journal of Heart and Lung Transplantation, 2010
- Clinical epidemiology of heart failureHeart, 2007
- Clinical Use of the Total Artificial HeartNew England Journal of Medicine, 1984